<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LANSOPRAZOLE</span><br/>(lan'so-pra-zole)<br/><span class="topboxtradename">Prevacid, </span><span class="topboxtradename">Prevacid IV, </span><span class="topboxtradename">Prevacid SoluTab<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antisecretory</span>; <span class="classification">proton pump inhibitor</span><br/><b>Prototype: </b>Omeprazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg, 30 mg sustained release capsules; 15 mg, 30 mg orally disintegrating tablets; 15 mg, 30 mg packets for suspension; 30 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Belongs to a class of antisecretory compounds that are gastric acid pump inhibitors. Specifically, it suppresses gastric acid
         secretion by inhibiting the H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme [the acid (proton H<sup>+</sup>) pump] in the parietal cells. Lansoprazole does not exhibit anticholinergic or H<sub>2</sub>-histamine antagonist properties.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Suppresses gastric acid formation in the stomach.</p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term treatment of duodenal ulcer (up to 4 wk) and erosive esophagitis (up to 8 wk), pathologic hypersecretory disorders,
         gastric ulcers; in combination with clarithromycin and amoxicillin for <i>Helicobacter pylori.</i> Gastroesophageal reflux disease.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to lansoprazole, severe hepatic impairment, proton pump inhibitors (PPIs) hypersensitivity, lactation, infants.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic disease, pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Duodenal Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg once daily times 4 wk<br/><br/><span class="indicationtitle">Erosive Esophagitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30 mg once daily times 8 wk, then decrease to 15 mg once daily <span class="rdroute">IV</span> 30 mg once daily for up to 7 days<br/><br/><span class="indicationtitle">GERD</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg once daily for up to 8 wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>111 y</i> 1.5 mg/kg/d (max: 30 mg/d)<br/><br/><span class="indicationtitle">Hypersecretory Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg once daily (max: 120 mg/d in divided doses), may need to be adjusted for hepatic impairment<br/><br/><span class="indicationtitle">
<i>H. pylori</i>
</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30 mg b.i.d. times 2 wk, in combination with 2 antibiotics<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>
<i>All forms:</i> Administer dosage 30 min a.c. Give once daily dose before breakfast.
         </li>
<li>Give at least 30 min prior to any concurrent sucralfate therapy.</li>
<li>Do not crush or chew capsules. Capsules can be opened and granules sprinkled on food or mixed with 40 mL of apple juice and
            administered through an NG tube. Do not crush or chew granules.
         </li>
<li>
            				Note: Disintegrating tablets contain phenylalanine and should not be used for patients with PKU. Capsule and syrup formulations
            do not contain phenylalanine.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Add 5 mL of sterile water for injection to each 30 mg vial to yield 6 mg/mL. Swirl gently to mix. Further dilute in 50 mL
                  of NS, RL, or D5W. If reconstituted with NS or LR, administer within 24 h. If reconstituted with D5W, administer within 12
                  h.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse over 30 min through the in-line filter provided. Use a dedicated line or a Y-site; flush Y-site with NS before and
                  after administration. Do <small>NOT</small> give IV push. Immediately stop infusion if precipitation or discoloration occurs.  
               </p>
</td>
</tr>
</table>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive, Y-site:</span> Do not administer with other drugs or diluents. 
      </p>
<ul>
<li>Reconstituted solution can be held for 1 h at 25° C (77° F) before further dilution.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CNS:</span> Fatigue, dizziness, headache. <span class="typehead">GI:</span> Nausea, <span class="speceff-common">diarrhea,</span> constipation, anorexia, increased appetite, thirst elevated serum transaminases (AST, ALT). <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease <b>theophylline</b> levels. <b>Sucralfate</b> decreases lansoprazole bioavailability. May interfere with absorption of <b>ketoconazole,</b>
<b>digoxin,</b>
<b>ampicillin,</b> or <span class="classification">iron salts</span>.  <span class="typehead">Food:</span> Food reduces peak lansoprazole levels by 50%. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract after leaving stomach; unstable in acidic media. <span class="typehead">Onset:</span> Acid reduction within 2 h; ulcer relief within 1 wk. <span class="typehead">Peak:</span> 1.53 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> 97% bound to plasma proteins. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450 system. <span class="typehead">Elimination:</span> 1425% excreted in urine as metabolites; part of dose eliminated in bile and feces. <span class="typehead">Half-Life:</span> 1.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor CBC, kidney &amp; liver function tests, and serum gastric levels periodically.</li>
<li>Monitor for therapeutic effectiveness of concurrently used drugs that require an acid medium for absorption (e.g., digoxin,
            ampicillin, ketoconazole).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician of significant diarrhea.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>